Per ARTURSSON  SITE    

  • J Cell Physiol. 2021;In press. Hepatocyte size fractionation allows dissection of human liver zonation. Ölander M, Wegler C, Flörkemeier I, Treyer A, Handin N, Pedersen JM, Vildhede A, Mateus A, LeCluyse EL, Urdzik J, Artursson P. PubMed
  • Mol Pharm. 2021;In press. Influence of proteome profiles and intracellular drug exposure on differences in CYP cctivity in donor-matched human liver microsomes and hepatocytes. Wegler C, Matsson P, Krogstad V, Urdzik J, Christensen H, Andersson TB, Artursson P. PubMed
  • J Pharm Sci. 2021;110:388-396. Expanding the efflux in vitro assay toolbox: A CRISPR-Cas9 edited MDCK cell line with human BCRP and completely lacking canine MDR1. Wegler C, Gazit M, Issa K, Subramaniam S, Artursson P, Karlgren M. PubMed
  • Clin Pharmacol Ther. 2021;109:762-771. Proteomics-Informed Prediction of Rosuvastatin plasma profiles in patients with a wide range of body weight. Wegler C, Prieto Garcia L, Klinting S, Robertsen I, Wiśniewski JR, Hjelmesaeth J, Åsberg A, Jansson-Löfmark R, Andersson TB, Artursson P. PubMed
  • Chem Med Chem. 2020;15:1862-1874. The critical role of passive permeability in designing successful drugs. Di L, Artursson P, Avdeef A, Benet LZ, Houston JB, Kansy M, Kerns EH, Lennernäs H, Smith DA, Sugano K. PubMed
  • Liver Int. 2020;40:1770-1780. Cell-type-resolved proteomic analysis of the human liver. Ölander M, Wiśniewski JR, Artursson P. PubMed
  • Pharm Res. 2019;36:178. A cell-free approach based on phospholipid characterization for determination of the cell specific unbound drug fraction (fu,cell). Treyer A, Walday S, Boriss H, Matsson P, Artursson P. PubMed
  • Drug Metab Dispos. 2020;48:8-17. A comparative analysis of Cytochrome P450 activities in paired liver and small intestinal samples from patients with obesity. Krogstad V, Peric A, Robertsen I, Kringen MK, Wegler C, Angeles PC, Hjelmesæth J, Karlsson C, Andersson S, Artursson P, Åsberg A, Andersson TB, Christensen H. PubMed
  • Pharm Res. 2019;36:178. A cell-free approach based on phospholipid characterization for determination of the cell specific unbound drug fraction (fu,cell). Treyer A, Walday S, Boriss H, Matsson P, Artursson P. PubMed
  • Clin Pharmacol Ther. 2019;106:525-543. Towards a consensus on applying quantitative LC-MS/MS proteomics in translational pharmacology research: A white paper. Prasad B, Achour B, Artursson P, Hop CE, Lai Y, Smith PC, Barber J, Wisniewski JR, Spellman D, Uchida Y, Zientek M, Unadkat JD, Rostami-Hodjegan A. PubMed
  • Sci Rep. 2019;9:5850. Improved predictions of time-dependent drug-drug interactions by determination of cytosolic drug concentrations. Filppula AM, Parvizi R, Mateus A, Baranczewski P, Artursson P. PubMed   
  • Arch Toxicol. 2019;93:819-829. A simple approach for restoration of differentiation and function in cryopreserved human hepatocytes. Ölander M, Wiśniewski JR, Flörkemeier I, Handin N, Urdzik J, Artursson P. PubMed
  • J Proteome Res. 2019;18:217-224. Multiple-enzyme-digestion strategy improves accuracy and sensitivity of label- and standard-free absolute quantification to a level that is achievable by analysis with stable isotope-labeled standard ppiking. Wiśniewski JR, Wegler C, Artursson P. PubMed
  • Drug Metab Dispos. 2018;46:1776-1786. CRISPR-Cas9: A new addition to the drug metabolism and disposition tool Box. Karlgren M, Simoff I, Keiser M, Oswald S, Artursson P. PubMed
  • Mol Pharm. 2018;15:2224-2233. Intracellular drug bioavailability: effect of neutral lipids and phospholipids. Treyer A, Mateus A, Wiśniewski JR, Boriss H, Matsson P, Artursson P. PubMed
  • Drug Metab Dispos. 2018;46:387-396. Direct quantification of cytochromes P450 and drug transporters. A rapid, targeted mass spectrometry-based immunoassay panel for tissues and cell culture lysates. Weiß F, Hammer HS, Klein K, Planatscher H, Zanger UM, Norén A, Wegler C, Artursson P, Joos TO, Poetz O. PubMed
  • Mol Pharm. 2017;14:3142-3151. Variability in mass spectrometry-based quantification of clinically relevant drug transporters and drug metabolizing enzymes. Wegler C, Gaugaz FZ, Andersson TB, Wiśniewski JR, Busch D, Gröer C, Oswald S, Norén A, Weiss F, Hammer HS, Joos TO, Poetz O, Achour B, Rostami-Hodjegan A, van de Steeg E, Wortelboer H, Artursson P. PubMed
  • J Pharm Sci. 2017; in press. A CRISPR-Cas9 generated Madin-Darby Canine Kidney expressing human MDR1 without endogenous canine MDR1 (cABCB1): an improved tool for drug efflux studies. Karlgren M, Simoff I, Backlund M, Wegler C, Keiser M, Handin N, Müller J, Lundquist P, Jareborg AC, Oswald S, Artursson P. PubMed
  • Proc Natl Acad Sci U S A. 2017;114:E6231-E6239. Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery. Mateus A, Gordon LJ, Wayne GJ, Almqvist H, Axelsson H, Seashore-Ludlow B, Treyer A, Matsson P, Lundbäck T, West A, Hann MM, Artursson P. PubMed
  • J Proteomics. 2016;136:234-47. In-depth quantitative analysis and comparison of the human hepatocyte and hepatoma cell line HepG2 proteomes. Wiśniewski JR, Vildhede A, Norén A, Artursson P. PubMed
  • Eur J Pharm Sci. 2017;103:70-76. Substrate and method dependent inhibition of three ABC-transporters (MDR1, BCRP, and MRP2). Pedersen JM, Khan EK, Bergström CAS, Palm J, Hoogstraate J, Artursson P. PubMed
  • Sci Rep. 2017;7:43047. Intracellular drug bioavailability: a new predictor of system dependent drug disposition. Mateus A, Treyer A, Wegler C, Karlgren M, Matsson P, Artursson P. PubMed
  • J Biomol Screen. 2016;21(2):156-64. Direct measurement of intracellular compound concentration by RapidFire Mass Spectrometry offers insights into cell permeability. Gordon LJ, Allen M, Artursson P, Hann MM, Leavens BJ, Mateus A, Readshaw S, Valko K, Wayne GJ, West A. PubMed
  • Anal Biochem. 2016;509:82-88. Subcellular fractionation of human liver reveals limits in global proteomic quantification from isolated fractions. Wiśniewski JR, Wegler C, Artursson P. PubMed
  • Trends Pharmacol Sci. 2016;37:243-5. The need for speed-kinetic limits of drug transporters. Matsson P, Lundquist P, Artursson P. PubMed
  • J Pharm Sci. 2016;105:1017-21. Complete knockout of endogenous Mdr1 (Abcb1) in MDCK Cells by CRISPR-Cas9. Simoff I, Karlgren M, Backlund M, Lindström AC, Gaugaz FZ, Matsson P, Artursson P. PubMed
  • J Pharm Sci. 2016;105:817-27. The Proteome of filter-grown Caco-2 Cells with a focus on proteins involved in drug disposition. Ölander M, Wiśniewski JR, Matsson P, Lundquist P, Artursson P. PubMed
  • Drug Metab Dispos. 2016;44:505-16. Mechanistic modeling of Pitavastatin disposition in Sandwich-Cultured Human Hepatocytes: a proteomics-informed bottom-up approach. Vildhede A, Mateus A, Khan EK, Lai Y, Karlgren M, Artursson P, Kjellsson MC. PubMed
  • Adv Drug Deliv Rev. 2016;106(Pt B):256-276. Oral absorption of peptides and nanoparticles across the human intestine: Opportunities, limitations and studies in human tissues. Lundquist P, Artursson P. PubMed
  • Science. 2015;347:716-7. Structural biology. Breaking the intestinal barrier to deliver drugs. Artursson P, Knight SD. PubMed
  • J Proteome Res. 2015;14:3305-14. Comparative proteomic analysis of human liver tissue and isolated hepatocytes with a focus on proteins determining drug exposure. Vildhede A, Wiśniewski JR, Norén A, Karlgren M, Artursson P. PubMed
  • Trends Pharmacol Sci. 2015;36:255-62. Quantifying the impact of transporters on cellular drug permeability. Matsson P, Fenu LA, Lundquist P, Wiśniewski JR, Kansy M, Artursson P. PubMed
  • Drug Metab Dispos. 2014;42:1210-8. Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions.Vildhede A, Karlgren M, Svedberg EK, Wisniewski JR, Lai Y, Norén A, Artursson P. PubMed
  • Mol Pharm. 2014;11:1727-38. Passive lipoidal diffusion and carrier-mediated cell uptake are both important mechanisms of membrane permeation in drug disposition. Smith D, Artursson P, Avdeef A, Di L, Ecker GF, Faller B, Houston JB, Kansy M, Kerns EH, Krämer SD, Lennernäs H, van de Waterbeemd H, Sugano K, Testa B. PubMed
  • J Med Chem. 2014;57:3005-10. A high-throughput cell-based method to predict the unbound drug fraction in the brain. Mateus A, Matsson P, Artursson P. PubMed
  • J Med Chem. 2014;57:2746-54. Impact of stereospecific intramolecular hydrogen bonding on cell permeability and physicochemical properties. Over B, McCarren P, Artursson P, Foley M, Giordanetto F, Grönberg G, Hilgendorf C, Lee MD 4th, Matsson P, Muncipinto G, Pellisson M, Perry MW, Svensson R, Duvall JR, Kihlberg J. PubMed
  • Eur J Pharm Sci. 2014;57:173-99. Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs. Bergström CA, Holm R, Jørgensen SA, Andersson SB, Artursson P, Beato S, Borde A, Box K, Brewster M, Dressman J, Feng KI, Halbert G, Kostewicz E, McAllister M, Muenster U, Thinnes J, Taylor R, Mullertz A. PubMed
  • Mol Pharm. 2013;10:4252-62. Combined in vitro-in vivo approach to assess the hepatobiliary disposition of a novel oral thrombin inhibitor. Matsson EM, Eriksson UG, Palm JE, Artursson P, Karlgren M, Lazorova L, Brännström M, Ekdahl A, Dunér K, Knutson L, Johansson S, Schützer KM, Lennernäs H. PubMed
  • Toxicol Sci. 2013;136:328-43. Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Pedersen JM, Matsson P, Bergström CA, Hoogstraate J, Norén A, LeCluyse EL, Artursson P. PubMed
  • Mol Pharm. 2013;10:3152-63. An integrated in vitro model for simultaneous assessment of drug uptake, metabolism, and efflux. Neve EP, Artursson P, Ingelman-Sundberg M, Karlgren M. PubMed
  • Mol Pharm. 2013;10:2467-78. Rapid measurement of intracellular unbound drug concentrations. Mateus A, Matsson P, Artursson P. PubMed
  • Clin Pharmacol Ther. 2013;94:30-2. Computational prospecting for drug-transporter interactions. Matsson P, Artursson P. PubMed
  • J Med Chem. 2012;55:4740-63. Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P. PubMed
  • Drug Discov Today. 2012;17:905-12. Evidence-based approach to assess passive diffusion and carrier-mediated drug transport. Di L, Artursson P, Avdeef A, Ecker GF, Faller B, Fischer H, Houston JB, Kansy M, Kerns EH, Krämer SD, Lennernäs H, Sugano K. PubMed
  • Pharm Res. 2012;29:411-26. In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. Karlgren M, Ahlin G, Bergström CA, Svensson R, Palm J, Artursson P. PubMed
  • Nat Rev Drug Discov. 2010;9:597-614. Coexistence of passive and carrier-mediated processes in drug transport. Sugano K, Kansy M, Artursson P, Avdeef A, Bendels S, Di L, Ecker GF, Faller B, Fischer H, Gerebtzoff G, Lennernaes H, Senner F. PubMed
  • Pharmacogenomics J. 2011;11:400-11.Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions. Ahlin G, Chen L, Lazorova L, Chen Y, Ianculescu AG, Davis RL, Giacomini KM, Artursson P. PubMed
  • Drug Metab Dispos. 2009;37:2275-83. Endogenous gene and protein expression of drug-transporting proteins in cell lines routinely used in drug discovery programs. Ahlin G, Hilgendorf C, Karlsson J, Szigyarto CA, Uhlén M, Artursson P. PubMed
  • Pharm Res. 2009;26:1816-31. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Matsson P, Pedersen JM, Norinder U, Bergström CA, Artursson P. PubMed
  • J Med Chem. 2008;51:5932-42. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, Artursson P. PubMed
  • J Med Chem. 2008;51:3275-87. Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P. PubMed

PubMed

Uppsala, Sweden

full_image.jpg

Last update: April 2021